NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Market Cap:4.1M; Shares Outstanding:978.2K; Short Interest: 5.2%; Q3 2019(9/30/19): Cash 3.19. Loss 1.41M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 18，no change
Shares hold: 191.9k shares. no change
shares% hold: 19.61%，no change